DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service
Food and Drug Administration

Memorandum

Date: DEC 17 2002

From: Consumer Safety Officer, Division of Standards and Labeling Regulations, Office of Nutritional Products, Labeling and Dietary Supplements, HFS-821

Subject: 75-Day Premarket Notification of New Dietary Ingredients

To: Dockets Management Branch, HFA-305

Subject of the Notification:	Lamila (La Mila)
Firm:	Herbal Powers, Inc.
Date Received by FDA:	March 18, 2002
90-Day Date:	June 16, 2002

In accordance with the requirements of section 413(a) of the Federal Food, Drug, and Cosmetic Act, the attached 75-day premarket notification and related correspondence for the aforementioned substance should be placed on public display in docket number 95S-0316 as soon possible since it is past the 90-day date. Thank you for your assistance.

Rhonda R. Kane

Rhonda R. Kane, M.S., R.D.

Attachments

95S-0316

RPT122

DEPARTMENT OF HEALTH AND HUMAN SERVICES Public Health Service

Food and Drug Administration
College Park, MD

MAY 31 2002

Annie Eng
Herbal Powers, Inc.
2138 West Jackson Suite #2
Chicago, Ilinois 60612

Dear Ms. Eng:

This letter is in response to two separate notifications you submitted to the Food and Drug Administration (FDA) pursuant to 21 U.S.C. 350b(a)(2). FDA received and filed the notifications on March 18, 2002. Each notification concerns a different botanical that you assert is a new dietary ingredient. Proposed product names and the Latin binomial names for the ingredients are listed below as stated in your notifications, with the exception that the species names are not capitalized:

- Lamila capsule 270 mg [*Labisia pumila* F. Vill]
- El Jack capsule 290 mg [*Eurycoma longifolia* Jack]

Earlier, you submitted notifications for El Jack and Lamila that were dated January 28, 2002, and were received and filed by FDA on February 26, 2002. Mr. Gary Coody on my staff contacted you by phone to request clarification regarding the names for El Jack and Lamila and you responded with the authors' names as indicated above. The author designation, F. Vill, you submitted for the Latin binomial name *Labisia pumila* is incorrect. The correct Latin binomial name and author designation for this plant is *Labisia pumila* Benth. & Hook. f. For the purposes of this letter, *Labisia pumila* will be used to refer to the plant source of Lamila.

Your notification states that Lamila will contain 270 mg per capsule of powdered whole plant of *Labisia pumila*. The proposed label will instruct consumers to take 2 capsules twice daily one hour before meals. The indicated conditions of use and the proposed text of the label submitted for Lamila include the following statements: may help alleviate fatigue; soothe menopausal symptoms; harmonize female reproductive system and menstrual cycle; enhance women's overall vitality and youthfulness; strengthen uterus; firm breast; enhance overall postpartum recovery; and tighten pelvic muscle after delivery. The proposed label also includes cautionary statements for potential consumers to consult a medical professional if they are taking a prescription medicine, are pregnant or nursing a baby, and to immediately seek the advise of a healthcare professional in case of accidental ingestion or overdosage.

Your other notification states that El Jack will contain 290 mg per capsule of powdered root of *Eurycoma Longifolia* Jack with label instructions to take 2 capsules daily. The indicated conditions of use for El Jack include the following statements: may help increase the efficiency of the healing system by supporting a healthy immune system; improve overall energy levels; reduce fatigue and exhaustion; enhance overall male

sexual vitality; improve appetite and digestion; and tone skin and muscle. The proposed label also includes cautionary statements for potential consumers to consult a medical professional if they are taking a prescription medicine, are pregnant or nursing a baby, and to immediately seek the advise of a healthcare professional in case of accidental ingestion or overdosage.

The statement "help increase the efficiency of the healing system" may cause El Jack to be represented as a drug. Under 21 U.S.C. 321(g)(1)(B), a drug is defined as an article intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or other animals. Therefore, if you intend to make claims of this nature and you want El Jack to be evaluated for its use in the treatment of a disease, you should contact FDA's Center for Drug Evaluation and Research, Office of Compliance, HFD-310, 7520 Standish Place, Rockville, Maryland 20855.

The law at 21 U.S.C. 350b(a)(2) requires that a manufacturer or distributor submit certain information to FDA at least 75 days before a new dietary ingredient or a dietary supplement containing it is introduced or delivered for introduction into interstate commerce. This information must include the basis on which the manufacturer or distributor has concluded that the new dietary ingredient or a dietary supplement containing it will reasonably be expected to be safe. FDA reviews this information to determine whether it provides an adequate basis for such a conclusion. Under 21 U.S.C 350b(a)(2), there must be a history of use or other evidence of safety establishing that the dietary ingredient, when used under the conditions recommended or suggested in the product's labeling, will reasonably be expected to be safe. If this requirement is not met, the new dietary ingredient or dietary supplement containing it is deemed to be adulterated under 21 U.S.C. 342(f)(1)(B), because there is inadequate information to provide reasonable assurance that the new dietary ingredient does not present a significant or unreasonable risk of illness or injury.

FDA carefully considered the information in your notifications. We have significant concerns about the basis upon which you concluded that a dietary supplement containing *Eurycoma longifolia* or *Labisia pumila* is reasonably expected to be safe when used as recommended or suggested in the products' labeling. These concerns for each ingredient are discussed below.

El Jack

The history of use information provided in your notification states that *Eurycoma longifolia* is indigenous to Southeast Asia and Indo-China and has been used by the locals in folk medicine as a febrifuge and a remedy for "intermittent fevers." It also refers to *Eurycoma longifolia* as a "tree of 100 remedies." This history of use information lacks details on the amount, frequency and duration of use for the botanical and whether the plant parts or preparation used are the same as what you intend to market in El Jack. Without these details, it is not possible for FDA to determine how this information relates to your product.

Your notification also includes a photocopy and translation of a registration held by Tomrich Marketing with the Drug Control Authority of Malaysia for "E.L. Jack Capsule"

for the following approved indication: "traditionally used for improving energy, reduce body fatigue and enhance overall performance". You assert in your notification, but without supporting documentation, that over "20 million capsules of E.L. Jack Capsules have been sold in Asia since 1997 and that there have been no serious side effects or drug interactions reported to date when used as directed." FDA is not aware of any systematic collection of data related to adverse effects occurring in individuals using E.L. Jack capsules. Further, absence of adverse event reports does not necessarily mean a particular product or ingredient has not been or is not likely to be associated with an adverse event, nor does it provide adequate evidence of safety for El Jack.

Your notification also includes copies of what appear to be promotional materials and newspaper clippings from unidentified sources intermixed with research publications of *invitro* and *invivo* animal studies. Sources are not provided for several of the research publications. Medicinal benefits for *Eurycoma longifolia* stated in the materials include the following: aphrodisiac, androgenic, antiviral, antimalarial, antipyretic, antihistaminic, antiulcer, antianxiety, anticancer tumor, antihypertensive, antidysentery, and others. None of the papers directly assess safety nor do they provide any safety data for exposure of *Eurycoma longifolia* in humans. Furthermore, since the relationship between *invitro*, animal and human exposure is unknown, the applicability of these results to humans is unclear. Of additional concern is the possibility that *Eurycoma longifolia* may increase testosterone levels, as suggested by the Kwan *et. al.* paper. If this were confirmed in humans, it could pose a safety risk in men with prostate cancer or other medical conditions. A Certificate of Analysis included in your notification for the Malaysian *Eurycoma longifolia* capsule drug product indicates that it was assayed for glucocorticosteroids, but not for testosterone or any other androgenic compounds. In summary, your notification has provided no data or publications that can be used to assess the safety of El Jack capsule when used as you direct.

Lamila

Your notification states that *Labisia pumila* is indigenous to Southeast Asia and has been used by the local women for vitality and restoring youthfulness. This history of use information lacks details on the amount, frequency and duration of use for the botanical and whether the plant parts and preparation used are the same as what you intend to market in Lamila. Without these details, it is not possible for FDA to determine how this information relates to your product.

Your notification also includes a photocopy and translation of a registration held by Tomrich Marketing with the Drug Control Authority of Malaysia for "Labisia pumila capsules" for the following approved indication: "traditionally used for improving energy and women's health." You assert in your notification, but without supporting documentation, that over 2 million capsules of Labisia pumila capsules have been sold in Asia since 1999 and that there have been no serious side effects or drug interactions reported to date when used as directed. FDA is not aware of any systematic collection of data related to adverse effects occurring in individuals using Labisia pumila capsules. Further, absence of adverse event reports does not necessarily mean a particular product or ingredient has not been or is not likely to be associated with an adverse event, nor does it provide adequate evidence of safety for Lamila.

Also attached to your notification are what appear to be promotional materials and other articles from unidentified sources. The materials include statements of medicinal uses for *Labisia pumila* that include but are not limited to the following: treat dysmenorrhea, rheumatism, gonorrhea, and dysentery; support healthy vaginal flora to prevent irritation and infections; speed up healing of the womb and birth canal after childbirth; strengthen the uterus and bladder from slipping out of place; and alleviate flatulence. The articles state that *Labisia pumila* contains phytoestrogens. However, the notification contains only one abstract by Jamal *et. al.* that mentions the presence of weak phytoestrogens in *Labisia pumil*, but no data is provided. A Certificate of Analysis for the *Labisia pumila* drug product by Tomrich Marketing indicates that assays were performed for glucocosteroids but not for estrogens or other compounds known to have estrogenic activity. In summary, there is no information in the materials submitted in your notification to assess the safety of *Labisia pumila* when used as you direct.

Conclusions

For the reasons discussed above, the information in your notification on Lamila does not provide an adequate basis to conclude that it will reasonably be expected to be safe when used under the conditions recommended or suggested in the product's labeling. Also as stated above, because the information in your submission indicates that El Jack is represented as a drug and not a dietary supplement, it would be subject to regulation as a drug. Notwithstanding, even if it could be argued that El Jack is a dietary supplement, the information in your notification does not provide an adequate basis to conclude that it will reasonably be expected to be safe when used under the conditions recommended or suggested in the product's labeling. Therefore, Lamila and El Jack may be adulterated under 21 U.S.C. 342(f)(1)(B) as dietary supplements that contain the new dietary ingredients *Labisia pumila* or *Eurycoma longifolia* for which there is inadequate information to provide reasonable assurance that such ingredients do not present a significant or unreasonable risk of illness or injury. Introduction of such products into interstate commerce is prohibited under 21 U.S.C. 331(a) and (v).

Your notifications will be kept confidential for 90 days after the filing date. After June 16, 2002, the two notifications will be placed on public display at FDA's Docket Management Branch in docket number 95S-0316. However, any trade secret or otherwise confidential commercial information in the notifications will not be disclosed to the public. Prior to June 16, 2002, you may wish to identify in writing specifically what information you

believe is proprietary in each of your notifications for FDA's consideration. Nevertheless, our Center's Freedom of Information Officer has the authority to make the final decision about what information in the notifications should be redacted before they are posted at Dockets.

Please contact us at (301) 436-2371, if you have questions concerning this matter.

Sincerely yours,

Felicia B. Satchell

Felicia B. Satchell
Director
Division of Standards
and Labeling Regulations
Office of Nutritional Products, Labeling
and Dietary Supplements

Gary Coody
FDA
5100 Paintbranch Pkwy
HSF 805
College Park, MD 20740-3835

Dear Gary,

I have enclosed 4 copies of new letter for Eyrycoma Longifolia and 4 copies of new letter for Labisia Pumila. These new letters contain the latin author name for each botanical. Please disregard the old letters. Thank you.

Sincerely,

Annie Eng
Herbal Powers Inc.
2138 W. Jackson
Suite # 2
Chicago, IL 60612
H(312)280-1032
C(312)505-1318

FDA Notification of New Dietary Ingredients

Filed By: Herbal Powers
2138 W. Jackson Bvld
Suite # 2
Chicago, IL 60612
Tel: (312)280-1032
Cell: (312)505-1318
E-mail: tradereng@hotmail.com

Contract manufacturer:
Yanling Natural Hygiene Sdn. Bhd
51200 Kuala Lumpur
Malaysia

Distributor in Malaysia:
Tomrich Marketing Sdn Bhd
47000 Selangor
Malaysia

Dietary Supplement: *Lamila Capsule 270MG* ***Labisia Pumila (Author: F. VILL)***

Description of Product:

(1) Level of Dietary Ingredients: 270mg per capsule
Pure powder from the whole plant of Labisia Pumila

(2) Conditions of Use: Labisia Pumila may help alleviate fatigue and soothes menopausal symptoms. Research shows that the phytoestrogents in Labisia Pumila may help enhance women's overall vitally and youthfulness.

Labisia Pumila may strengthen uterus, firm breast and tighten pelvic muscle after delivery.

(3) History of Use: Labisia Pumila grows in the rainforest of the Southeast Asia. It has been used by the local women for vitality and restoring youthfulness. It is known for its beneficial effects for after delivery care, for harmonize women's reproductive system, and for establishing a regular menstrual cycle.

Labisia Pumila has been manufactured in capsules form by Tomrich since 1999. Tomrich has sold over 2 million capsules since 1999 in Asia. Labisia Pumila has been certified and approved by the Malaysia Drug Control Authority, National Pharmaceutical Control Bureau, Ministry of Health Malaysia and are manufactured under stringent Good Manufacturing Practices' (GMP) standards. The products are manufactured without adding any additives, preservatives, chemical, artificial flavors or color. No serious side effects or drug interactions have been reported to date when used as directed. For more information on historical use, please refer to the enclosed news

article and research report.

We have enclosed:

(1) Lab result from National Pharmaceutical Control Bureau (NPCB)
(ii) Approval certificates by Drug Control Authority, Ministry of Health Malaysia
(3) Registration Number of Labisia Pumila with Drug Control Authority, ministry of Health Malaysia
(4) Manufacturing & Sterilizing Process
(5) Proposed label for Labisia Pumila in the United States
(6) News article, research report for the product

Sincerely,

Annie Eng
H(312)280-1032
C(312)505-1318
E-mail:tradereng@hotmail.com

Suggested Use: take 2 capsules twice daily 1 hour before meal. The beneficial effects of supplements are build up gradually. Therefore it is recommended that this product is taken regularly to obtain continuous benefits.

Precautions: No serious side effects or drug interactions have been reported to date when used as directed. However, as with any supplement, consult a medical professional if you are taking a prescription medicine, are pregnant, or nursing a baby. In case of accidental ingestion/overdosage, seek the advise of a healthcare professional immediately. Keep out of reach of children.

Color variation is normal in this product
No artificial colors, flavors, or preservatives
Store in a cool dry place
DO NOT USE IF EITHER SEAL IS BROKEN OR MISSING

LA MILA

Labisia Pumila

270MG 60 CAPSULES

Labisia Pumila has been used for centuries by the local women in Southeast Asia for improving energy and overall women's vitality .Labisia Pumila may alleviate fatigue and soothes menopausal symptoms.. Research shows that Labisia Pumila contains phytocestrogents that may enhance overall postpartum recovery. Labisia Pumila may help harmonize female reproductive system and menstrual cycle..

This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure or prevent any disease.

Supplement Facts

Serving Size 2 Capsules
Servings per Container 30

Amount Per Serving	
Labisia Pumila Extract	540MG*

* Daily Value not established

Other Ingredients: Gelatin, Water

Distributed by Herbal Powers Inc
Chicago, IL 60612
Product of Malaysia
www..herbal-powers.com

LABSERVICE (M) SDN BHD (Company No: 119162-D)

A1-23 & 24, PJ Industrial Park,
Jalan Kemajuan, 46200 Petaling Jaya,
Selangor Darul Ehsan, Malaysia.
Tel : 03-7576016/7576381/7567499
Fax : 603-7576488

LAB. NO. LS/13789/99/ms(A)

DATE 17th June 1999

CERTIFICATE OF ANALYSIS

ONE SAMPLE OF LABISIA PUMILA (KACIP FATIMAH) CAPSULES SUNMITTED BY M/S. TOMRICH MARKETING SDN.BHD., KUALA LUMPUR ON 7/6/99 AND MARKED:-

BRAND NAME: LAMILA 270MG
MFG : 22.03.99
EXP : 21.03.2001

ANALYSIS		RESULTS	SPECIFICATIONS
STEROIDS			
Beclomethasone dipropionate	...	Negative	Negative
Betamethasone 17 - valerate	...	Negative	Negative
Cortisone acetate	...	Negative	Negative
Dexamethasone	...	Negative	Negative
Flumethasone	...	Negative	Negative
Hydrocortisone acetate	...	Negative	Negative
Prednisolone	...	Negative	Negative
Prednisone	...	Negative	Negative
MICROBIAL LIMIT TESTS			
Standard Plate Count per g @ 37 °C for 48 hours	...	1.0×10^3	5×10^4 max
Yeast & Moulds per g	...	Absent	5×10^2 max
E.coli per g (MPN)	...	Absent	Absent
Salmonella in 25 g	...	Absent	Absent
Pseudomonas aeruginosa per g	...	Absent	Absent
Staphylococcus aureus per g	...	Absent	Absent
Enterbacteria per g	...	Absent	Absent
HEAVY METALS			
Arsenic (as As)	, ppm ...	Not detected	5.0 max
Lead (as Pb)	, ppm ...	0.95	10.0 max
Mercury (as Hg)	, ppm ...	Not detected	0.5 max

The above specifications was obtained from National Pharmaceutical Control Bureau (NPCB) for registration under Phase III of the implementation of the Control of Drugs and Cosmetics Regulations, 1984.

LABSERVICE (M) SDN BHD

A1-23 & 24, PJ Industrial Park,
Jalan Kemajuan, 46200 Petaling Jaya,
Selangor Darul Ehsan, Malaysia.
Tel : 03-7576016/7576381/7567499
Fax : 603-7576488

DATE 17th June 1999

YOUR REF. :

OUR REF.: LS/13789/99/ms(A)

MINERALS				
Calcium	(as Ca)	, ppm	...	6731.65
Magnesium	(as Mg)	, ppm	...	3398.62
Zinc	(as Zn)	, ppm	...	18.20
Potassium	(as K)	, ppm	...	44.20
Iron	(as Fe)	, ppm	...	207.59

S. KHOO Dip App Chem & Sc (Melb.)
Grad I.A.C.I., A.M.I.C., M.A.C.S.
Director
LABSERVICE (M) SDN. BHD. (119182-D)

LSL/ph

Tomrich Marketing Sdn Bhd
Product Names: Lamila (MAL19991267TC)
Active Ingredients: Labisia Pumila
Dosage: 270mg per capsule

MANUFACTURING & STERILIZING PROCESS

Stage 1 : ***Preparation of raw materials***

Stage 2 : ***Encapsulating & Packing***

Labisia Pumila (Kacip Fatima) 是一種自然生長在東南亞熱帶雨林的細小、類似草本性質的植物。已能被持續的收割，只有根及葉子能被用來製造產品。並不附加任何防腐劑、人造調味料或化學藥物。

用量

每日2次，每次2粒膠囊，飯前一小時服用。

含量

每粒膠囊含有270mg Labisia Pumila
每瓶含有60粒膠囊。

活躍成份

Labisia Pumila (Kacip Fatima) 100%

PRODUCT INFORMATION

Labisia Pumila (Kacip Fatima) is a small, slightly woody herbaceous plant which grows naturally in the tropical rainforests of S E Asia. It is sustainably harvested and only the roots and leaves are used in manufacturing the product, without preservatives, additives, chemicals artificial flavours or colours.

INDICATION

Traditionally used for improving energy and women's health The beneficial effects of supplementation are built up gradually. It is therefore recommended that this product is taken regularly to obtain continuous benefits

DOSAGE

2 capsules twice daily, 1 hour before meal.

STORAGE

Keep in cool dry place, out of reach of children.

MAKLUMAT PRODUK

Labisia Pumila (Kacip Fatima) ialah sejenis tumbuhan herba renik yang tumbuh secara semula jadi di dalam hutan hujan tropika di Asia Tenggara Ia diambil secara mapan (tanpa memusnahkan habitat) dari kawasan hutan dan hanya akar dan daunnya sahaja digunakan dalam proses pengilangan produk ini, tanpa dicampur bahan pengawet, bahan tambahan, bahan kimia, perasa tiruan mahupun pewarna.

DOS

2 kapsul dua kali,
sejam sebelum makan

KANDUNGAN

270mg setiap kapsule
60 kapsules sebotol

BAHAN AKTIF

Labisia Pumila (Kacip Fatima) 100%

FUNGSI

LAMILA

Labisia Pumila

(Kacip Fatima)



Traditionally used for improving energy and women's health

MADE IN MALAYSIA
MAL19991267TC

Distributed By
HERBRICH FORESTS SDN BHD (129685-K)
No 10, Jalan S B Jaya 11,
Taman Industri S B Jaya,
47000 Sungai Buloh Selangor D E
www.herb-rich com

BATCH NO	1C58060
MANUFACTURED DATE	270701
EXPIRY DATE	260704

BORANG 1

PERATURAN-PERATURAN KAWALAN DADAH DAN KOSMETIK 1984

[Peraturan 8(8)]
PIHAK BERKUASA KAWALAN DADAH
KEMENTERIAN KESIHATAN MALAYSIA

PERAKUAN PENDAFTARAN

№ 028045

PERAKUAN No : MAL19991267TC

Nama dan alamat pemegang :

TOMRICH MARKETING SDN. BHD.

2, JALAN TIONG NAM
50350 KUALA LUMPUR.

BUTIR-BUTIR MENGENAI KELUARAN :

Nama LAMILA CAPSULE

Nama Pengilang YANLING NATURAL HYGIENE SDN. BHD.

Alamat Pengilang 1ST FLOOR, RESOURCE COMPLEX
33, JALAN SEGAMBUT ATAS
51200 KUALA LUMPUR.

No. Lesen Pengilang, (jika ada)

Keluaran di atas adalah didaftarkan tertakluk kepada syarat-syarat berikut :

SEMUA SYARAT PENDAFTARAN YANG DITETAPKAN OLEH PIHAK BERKUASA KAWALAN DADAH.

(Bersambung di atas kepingan lain yang dilampirkan kepada perakuan ini *)

Tempoh pendaftaran ini ialah dari 27/5/1999 19

hingga 27/5/2004 19

Tarikh .....

TAN SRI DATO' (DR) ABU BAKAR BIN DATO' SULEIMAN
Pengerusi,
Pihak Berkuasa Kawalan Dadah

* Potong jika tidak pakai.

Perakuan Dahulu No. .....

Tarikh dikeluarkan .....

DICETAK OLEH PERCETAKAN SINAR TENAGA

PERATURAN-PERATURAN KAWALAN DADAH DAN
KOSMETIK 1984

PIHAK BERKUASA KAWALAN DADAH
KEMENTERIAN KESIHATAN MALAYSIA

NAMA KELUARAN : LAMILA CAPSULE 270MG.

NO. PENDAFTARAN : MAL19991267TC

INDIKASI YANG DILULUSKAN :

Traditionally used for improving energy and women's health.

CHE MOHD. ZIN CHE AWANG
Setiausaha
Pihak Berkuasa Kawalan Dadah
Kementerian Kesihatan Malaysia

TRANSLATION

FORM 1

RULES OF DRUGS & COSMETICS-1984

(RULING 8(8))

DRUG CONTROL AUTHORITY
MINISTRY OF HEALTH
MALAYSIA

REGISTRATION

NO.: 028045

REGISTRATION NO: **MAL19991267TC**

Name and address of Holder:

TOMRICH MARKETING SDN BHD
2, JALAN TIONG NAM
50350 KUALA LUMPUR

PRODUCT DETAILS:

Name of Product : **LAMILA CAPSULE**

Name of Factory : **YANLING NATURAL HYGIENE SDN BHD**

Address of Factory: 1st FLOOR, RESOURCE COMPLEX
33, JALAN SEGAMBUT ATAS
51200 KUALA LUMPUR

Factory Licence No. (if available)

The above product follows all the stated conditions:

ALL CONDITIONS ARE SET BY THE **DRUG CONTROL AUTHORITY**

(continue on next page *)

Date of Registration is from : 27/5/1999
to : 27/5/2004

Date:

.....
Tan Sri Dato (Dr.) ABU BAKAR
BIN DATO SULEIMAM
Chairman
DRUG CONTROL AUTHORITY

*Cut here if not in use

Previous Registration No, ...

Date Issued.....

FORM 1

RULES OF DRUGS & COSMETICS-1984

DRUG CONTROL AUTHORITY
MINISTRY OF HEALTH
MALAYSIA

PRODUCT NAME : **LAMILA CAPSULE 270MG**

REGISTRATION NUMBER : **MAL19991267TC**

APPROVED INDICATION :

Traditionally used for improving energy and women's health.

CHE MOHD.ZIN CHE AWANG
SECRETARY
DRUG CONTROL AUTHORITY
MINISTRY OF HEALTH MALAYSIA

"Senarai Keluaran Berdaftar / List of Registered Products Database"
DRUG CONTROL AUTHORITY, MINISTRY OF HEALTH MALAYSIA

1 records matched your query: **mal19991267tc** (Search Criteria: Register Number)

Registration Number: MAL19991267TC
Product : LAMILA CAPSULE

Price : Not Available

Holder : TOMRICH MARKETING S/B
Address : NO.2,JLN TIONG NAM,

Manufacturer : YANLING NATURAL HYGIENE S/B
Address : 16 & 18,JLN S.B.JAYA 11,
TAMAN INDUSTRI S.B.JAYA,

Ingredients :